Cantor Fitzgerald Reaffirms Overweight Rating for Intellia Therapeutics (NASDAQ:NTLA)

Cantor Fitzgerald restated their overweight rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $65.00 target price on the stock. A number of other brokerages have also issued reports on NTLA. Wedbush reiterated a neutral rating and set a […]

Leave a Reply

Your email address will not be published.

Previous post Liontrust Asset Management (LON:LIO) Downgraded by Deutsche Bank Aktiengesellschaft
Next post TD Securities Cuts Coveo Solutions (TSE:CVO) Price Target to C$12.00